Literature DB >> 20816271

Therapeutic challenges in dystonia.

Ninith Kartha1.   

Abstract

Because dystonia can vary in clinical presentation and etiology, proper diagnosis and classification of these disorders are important in making therapeutic decisions. In primary dystonia, treatment is generally geared toward alleviating symptoms rather than curing the underlying condition, therefore severity of contractions, pain, and functional and social impact are also factors to consider in determining if and how to initiate therapy. On the other hand, if a secondary cause is identified, then it is often appropriate to direct treatment toward the underlying disorder. Treatment options include physical and occupational therapy, oral medications, botulinum toxin, and surgery. This article briefly reviews the clinical features, pathophysiology, and classification of dystonia before reviewing current therapeutic options. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20816271     DOI: 10.1016/j.ncl.2010.03.020

Source DB:  PubMed          Journal:  Neurol Clin        ISSN: 0733-8619            Impact factor:   3.806


  4 in total

1.  Prevalence, predictors, and perceived effectiveness of complementary, alternative and integrative medicine in adult-onset primary dystonia.

Authors:  Brandy M Fleming; Emiko L Schwab; Simonne S Nouer; Jim Y Wan; Mark S LeDoux
Journal:  Parkinsonism Relat Disord       Date:  2012-05-25       Impact factor: 4.891

2.  Selective and sustained α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor activation in cerebellum induces dystonia in mice.

Authors:  Xueliang Fan; Keryn E Hughes; H A Jinnah; Ellen J Hess
Journal:  J Pharmacol Exp Ther       Date:  2011-12-14       Impact factor: 4.030

Review 3.  Update on pediatric dystonias: etiology, epidemiology, and management.

Authors:  Emilio Fernández-Alvarez; Nardo Nardocci
Journal:  Degener Neurol Neuromuscul Dis       Date:  2012-04-11

Review 4.  Tetrabenazine: Spotlight on Drug Review.

Authors:  Navneet Kaur; Puneet Kumar; Sumit Jamwal; Rahul Deshmukh; Vinod Gauttam
Journal:  Ann Neurosci       Date:  2016-09-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.